医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Medworxx Patient Throughput Review Market Update

2014年12月24日 AM01:08
このエントリーをはてなブックマークに追加


 

TORONTO

Medworxx Solutions Inc. (“Medworxx”) (TSX VENTURE: MWX) today is pleased to issue the Q4/2014 market update for the Medworxx Patient Throughput Review (“PTR”) program. Since its introduction in 2013, the PTR has been widely accepted by hospitals and health systems internationally. The PTR methodology leverages the Medworxx Clinical Criteria Module software to unlock unique patient flow information to help organizations understand the scope of their patient flow issues and identify specific opportunities to improve quality and performance.

Management consulting companies, Medworxx clinical consultants and hospital process improvement groups are able to use the Medworxx Clinical Criteria Module to rapidly identify patient flow data, providing visibility into patient flow issues in the hospitals that they provide services to. Consulting companies and hospital process improvement groups are able to license the Medworxx software to deliver PTRs independent of Medworxx.

International deployment of the Medworxx PTR program continues; forty-four PTRs have been delivered in five countries: Australia, Canada, France, the United States and the United Kingdom. Since the last Market Update Report ended September 30, 2014, twelve PTRs were delivered: two were in Canada, two were in the United States, seven were in the United Kingdom, and one was in France. Medworxx and their consulting partners work with each site to analyze PTR data to support strategic decision making and improve performance and quality outcomes.

“We are excited to see PTR related activity continue in the regions. In the last two quarters we have completed PTRs both independently and together with consulting partners. The PTR is providing hospitals with the benchmark analysis needed to build a business case in order take steps to embed our Clinical Criteria Module for real-time operational use,” said Dan Matlow, CEO and President, Medworxx. “Our expectation is that we will soon start to see PTRs convert to operational use across many of our markets.”

Based on the positive progression of the company the company wishes to announce that its Board of Directors has struck a special committee to examine and consider strategic and financial alternatives available to Medworxx (the “Special Committee”). The Special Committee is composed of independent directors George Elliott (Chair), Har Grover, and Lee Matheson, and will consider a range of options with a view to enhancing shareholder value.

About Medworxx
Medworxx delivers health information technology solutions to over 350 hospitals internationally. Medworxx helps hospitals meet patient flow challenges, and requirements in compliance and education. Medworxx Clinical Criteria – flagship of Medworxx Patient Flow that includes electronic bed board and independent assessment components – currently serves 34% of the acute care beds in Canada. Founded in 2004, Medworxx is based in Toronto, ON, and publicly traded on the TSX Venture Exchange: MWX. For more information visit: http://www.medworxx.com.

Disclaimer
The statements made in this press release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the company’s expectations and projections. The TSX Venture Exchange has not reviewed this press release and neither approved nor disapproved the information contained in this press release.

CONTACT

Medworxx
Media Contact
Nadine Brown,
416-642-1278 x317
Director of Marketing & Media Relations
1-800-321-1591
nbrown@medworxx.com
or
Dan
Matlow, 416-642-1278 x311
President & Chief Executive Officer
1-800-321-1591
dmatlow@medworxx.com

www.medworxx.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表